佛慈制药(002644) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥251,478,344.31, representing a 6.28% increase year-over-year, while the year-to-date revenue reached ¥860,511,173.37, up 23.21% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was ¥2,065,930.91, a 25.94% increase year-over-year, with a year-to-date net profit of ¥59,119,316.28, reflecting an 11.80% increase[5]. - The company reported a basic earnings per share of ¥0.0040 for Q3 2023, which is a 25.00% increase compared to the same period last year[5]. - Total operating revenue for the third quarter reached ¥860,511,173.37, an increase of 23.2% compared to ¥698,414,186.50 in the same period last year[29]. - The net profit for Q3 2023 was CNY 59,034,535.14, an increase from CNY 53,194,707.79 in Q3 2022, representing a growth of approximately 10.5%[30]. - Operating profit for Q3 2023 reached CNY 75,246,927.61, compared to CNY 66,060,087.49 in the same period last year, indicating an increase of about 13.5%[30]. - The total profit for Q3 2023 was CNY 74,294,049.19, an increase from CNY 61,223,350.72 in Q3 2022, reflecting a growth of approximately 21.5%[30]. - The company reported a total comprehensive income of CNY 59,073,041.85 for Q3 2023, compared to CNY 53,242,866.82 in Q3 2022, marking an increase of about 10.5%[31]. - Basic and diluted earnings per share for Q3 2023 were both CNY 0.1158, up from CNY 0.1035 in Q3 2022, representing an increase of approximately 22.3%[31]. Research and Development - Research and development expenses increased by 48.27% year-over-year to ¥21,266,535.43, indicating a focus on enhancing research collaborations and projects[12]. - Research and development expenses increased to ¥21,266,535.43, representing a rise of 48.5% compared to ¥14,343,482.37 in the prior year[29]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥2,562,119,394.41, a decrease of 0.95% from the end of the previous year[5]. - The total assets as of September 30, 2023, were ¥2,562,119,394.41, slightly down from ¥2,586,568,848.41 at the beginning of the year[26]. - Current assets totaled ¥1,271,079,636.98, a decrease from ¥1,291,068,156.43 at the start of the year[26]. - The company's cash and cash equivalents decreased to ¥305,731,854.04 from ¥396,452,956.90 at the beginning of the year, reflecting a decline of 23%[26]. - Total liabilities decreased to ¥794,105,941.77 from ¥852,595,587.62, indicating a reduction of approximately 6.8%[27]. - The company’s total liabilities decreased by 54.54% for taxes payable, mainly due to the payment of 2022 year-end taxes[8]. - The equity attributable to shareholders increased to ¥1,748,997,238.01 from ¥1,715,389,713.37, showing a growth of 1.96%[27]. - Inventory levels rose to ¥379,711,659.83, up from ¥350,407,267.75, marking an increase of 8.4%[26]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥51,220,928.10 year-to-date, which is a 10.46% increase in outflow compared to the previous year[5]. - The cash flow from operating activities showed a net outflow of CNY 51,220,928.10 in Q3 2023, an improvement compared to the outflow of CNY 57,205,628.31 in Q3 2022[33]. - The company experienced a net cash outflow from financing activities of CNY 23,535,288.88 in Q3 2023, compared to an outflow of CNY 19,319,303.33 in Q3 2022[33]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,019[14]. - The largest shareholder, Lanzhou Foci Pharmaceutical Industry Development Group Co., Ltd., holds 61.63% of shares, totaling 314,713,676 shares, with 150,000,000 shares pledged[14]. - The company’s actual controller changed from Lanzhou State-owned Assets Supervision and Administration Commission to Gansu Provincial State-owned Assets Investment Group Co., Ltd., which indirectly controls 61.63% of the company’s issued shares[17]. - A mandatory tender offer was triggered by Gansu Guotou, covering 195,943,324 shares, which is 38.37% of the total share capital, at a price of RMB 9.55 per share[18]. - During the tender offer period from September 22, 2023, to October 23, 2023, 4,083,860 shares were accepted from 66 accounts[18]. - The company disclosed that the pledge and re-pledge of 150,000,000 shares by the controlling shareholder accounted for 29.37% of the total share capital[16]. - The company has not identified any related party relationships among the other shareholders listed in the top ten shareholders[15]. - The company’s stock distribution remains compliant with listing conditions following the completion of the tender offer[18]. - The company has undergone multiple disclosures regarding the changes in actual control and the tender offer process throughout 2023[19][20][23]. - The company’s stock was suspended during the tender offer period and resumed trading after the offer concluded[24]. Other Financial Metrics - Investment income for Q3 2023 was ¥1,192,877.25, a 134.85% increase compared to the previous year, attributed to profits from associated companies[12]. - The company reported a tax expense of CNY 15,259,514.05 for Q3 2023, compared to CNY 8,028,642.93 in Q3 2022, which is an increase of about 90.5%[30]. - The company experienced a significant reduction in contract liabilities, down 68.45% from the beginning of the year, primarily due to the settlement of prior sales orders[8].